Clinical Scorecard: New Treatments for Sickle Cell Disease

At a Glance

Key Highlights

• SCR is a sight-threatening complication of sickle cell disease, with increasing prevalence due to improved SCD management.
• HbSC genotype carries a higher risk of proliferative sickle cell retinopathy compared to HbSS, a phenomenon known as the 'sickle cell paradox.'
• Multimodal imaging techniques enhance detection and monitoring of SCR.
• Management strategies are stage-dependent, with observation being key in early stages.
• Scatter laser photocoagulation is the primary intervention for high-risk PSCR.

Guideline-Based Recommendations

Diagnosis

• Baseline dilated fundus examination at age 10, with repeat screenings every 1-2 years for asymptomatic patients.

Management

• Observation for nonproliferative and early proliferative stages; scatter laser photocoagulation for high-risk PSCR.

Monitoring & Follow-up

• Use of multimodal imaging for ongoing assessment of retinal changes.

Risks

• Increased risk of retinal vascular occlusions in HbSS patients, including central and branch retinal artery occlusions.

Patient & Prescribing Data

Over 100,000 individuals in the U.S. with sickle cell disease.

Spontaneous regression of neovascularization occurs in a significant percentage of cases.

Clinical Best Practices

• Utilize multimodal imaging for early detection and monitoring of SCR.
• Implement risk stratification based on genotype for screening intervals.
• Consider conservative management in early stages due to potential for spontaneous regression.

References

• Sickle Cell Disease Overview
• Guidelines for Sickle Cell Retinopathy Management